Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy
NCT ID: NCT03212755
Last Updated: 2017-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
75 participants
INTERVENTIONAL
2017-08-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T-regulatory Cells in Diabetic Type Two Nephropathy
NCT03591939
Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD
NCT06069076
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
NCT05061459
Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy
NCT05695573
To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy
NCT01163591
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
25 diabetic patients without diabetic nephropathy
serum immunoglobulin G level
measurement of the serum level as a marker of diabetic complications
group 2
25 type 2 diabetic patients with diabetic nephropathy
serum immunoglobulin G level
measurement of the serum level as a marker of diabetic complications
group 3
25 healthy subjects
serum immunoglobulin G level
measurement of the serum level as a marker of diabetic complications
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
serum immunoglobulin G level
measurement of the serum level as a marker of diabetic complications
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnant and lactating females ,
* patients with any congenital disease , Infection , Smokers , alcoholics , and drug abusers .
30 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seham Mohammed Ali
principal investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRUD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.